Activist Investor Starboard Value Takes $1B Stake in Pfizer, Calls for Strategic Overhaul

Activist investor Starboard Value has acquired a $1 billion stake in Pfizer to push for strategic changes in the U.S. pharmaceutical giant. This investment comes as Pfizer contends with declining sales of its COVID-19 vaccines and treatments, underwhelming sales for its RSV vaccine, and failed clinical trials for an obesity medication.

Former Pfizer Executives to Aid Starboard’s Efforts

Starboard has approached Ian Read, Pfizer’s CEO until 2019, and Frank D’Amelio, who served as CFO until 2021. Both former executives are interested in helping Starboard steer the company toward renewed growth.

Stock Price Decline Post-COVID Success

Albert Bourla, who became CEO in 2019, was key in partnering with BioNTech to develop Pfizer's COVID-19 vaccine. However, as pandemic demand wanes, the company’s stock has plummeted from approximately $41 to $28.58 as of last Friday, reflecting concerns over weakened vaccine demand and disappointing new product launches.

Aggressive Acquisitions Draw Scrutiny

Since 2020, Pfizer has made over $70 billion in acquisitions, including major deals like Seagen for $43 billion, Biohaven for $13 billion, Arena for $6 billion, Global Blood Therapeutics for $5 billion, and Trillium for $2 billion. The acquisitions have raised investor concerns, especially regarding GBT’s sickle cell drug, which faced market withdrawal due to severe side effects and discontinuation of related studies.

Starboard’s History of Corporate Overhauls

Known for pushing changes in major companies like News Corp, Salesforce, and Match Group, Starboard Value's influence could lead to significant shifts in Pfizer's strategic direction.

The Wall Street Journal first reported Starboard’s Pfizer stake. Neither Pfizer nor Starboard has officially commented on the investment or potential next steps.